The global benign prostatic hyperplasia surgical devices market by product type (Resectoscopes, Radiofrequency Ablation Devices, Urology Lasers, Prostatic Stents, Implants, and Others), end user (Hospitals and Ambulatory Surgery Centers) and region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 375.9 million in 2016 and is projected to exhibit a CAGR of 7.5% over the forecast period (2017 – 2025). Introduction of minimally invasive therapies such as implants, transurethral needle ablation (TUNA), prostatic artery embolization (PAE) is expected to attract the majority of the patients, who are currently opting for drugs, which in turn is expected to boost the growth of benign prostatic surgical devices market. The lucrative benign prostatic surgical devices market has witnessed multiple mergers, acquisition and product launches in recent years and the company involved in these activities varies from leading medical devices companies such as Medtronic Plc, Boston Scientific Corporation and Olympus Corporation to innovative startups such as NeoTract, Inc., and ProArc Medical. In 2011, Urologix, Inc. and Medtronic Plc struck a deal, as a part of which Urologix, Inc., received license for Prostiva. Urologix is a company focused on benign prostatic hyperplasia therapy. In 2016, Urologix, Inc. sold its assets to private buyer following default on debt to be paid to Medtronic Plc. In 2015, Boston Scientific Corporation acquired the male urology portfolio of American Medical Systems, which had generated more than US$ 100 million in last few years from devices for the treatment of benign prostatic hyperplasia. The company had various products for BPH in their portfolio including popular laser devices such as GreenLight HPS and GreenLight XPS laser therapy.
Browse 27 Market Data Tables and 22 Figures spread through 167 Pages and in-depth TOC on Benign Prostatic Hyperplasia Surgical Devices Market by Product Type (Resectoscopes, Radiofrequency Ablation Devices, Urology Lasers, Prostatic Stents, Implants and Others), End User (Hospitals and Ambulatory Surgery Centers) and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2025.
To know the latest trends and insights prevalent in the benign prostatic hyperplasia surgical devices market, click the link below:
NoeTract, Inc. received CE approval for its product, UroLift Systems in 2010 and de novo 510(k) approval from U.S. FDA in 2013. Another implant manufacturer, ProArc Medical is awaiting CE approval for its product, ClearRing. In June 2017, Merit Medical Systems, Inc. manufacturer of disposable devices received FDA approval for benign prostatic hyperplasia for its product, Embosphere Microspheres. In May 2017, NxThera, Inc., a manufacturer of radiofrequency devices for benign prostatic hyperplasia announced that the product, RezÅ«m System has been used to treat more than 10,000 patients suffering from the disease across the U.S. and Europe.
Key Takeaways of the Benign Prostatic Hyperplasia Surgical Devices Market:
Major players operating in the benign prostatic hyperplasia surgical devices market include Olympus Corporation, Boston Scientific Corporation, Medifocus Inc., KARL STORZ SE & Co. KG, NxThera, Inc., ProArc Medical, Lisa Laser Products OHG, and Richard Wolf Gmbh.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.